Forskolin is a potent activator known for its ability to stimulate adenylate cyclase directly, leading to an increase in intracellular cAMP levels. This rise in cAMP results in the activation of protein kinase A (PKA), which is known to phosphorylate a myriad of proteins within the cell. Should TMEM220 be a substrate for PKA, forskolin's effect would enhance its activity through phosphorylation. Dibutyryl-cAMP (db-cAMP) functions as a cell-permeable analog of cAMP, effectively bypassing upstream receptors and directly activating PKA, which can then modify the function of TMEM220 if it lies within PKA's scope of action. Ionomycin and A23187 are calcium ionophores that dramatically increase the intracellular calcium concentration, a crucial second messenger in numerous signaling pathways. This influx of calcium can activate calcium-dependent kinases, which, if TMEM220 is among their substrates, could result in its phosphorylation and activation. The diversity in the cellular responses to increased calcium levels underscores the potential for wide-ranging effects on TMEM220 activity.
Another activator, PMA, targets protein kinase C (PKC), which is involved in a variety of cellular functions. PKC phosphorylates numerous proteins; thus, if TMEM220 is a target, PMA could modulate its activity through PKC activation. This represents another pathway by which TMEM220 activity could be modulated through phosphorylation events. LY294002, PD98059, Rapamycin, Y-27632, SB203580, U0126, and SP600125, can indirectly lead to the activation of TMEM220. These compounds, despite their primary inhibitory roles on specific kinases or signaling pathways like PI3K, MEK, mTOR, ROCK, p38 MAPK, and JNK-may cause a compensatory activation in other pathways that converge on TMEM220. LY294002's inhibition of PI3K can result in compensatory responses that activate related pathways affecting TMEM220, while PD98059's inhibition of MEK may adjust related signaling networks that could lead to TMEM220 activation. Rapamycin's suppression of mTOR might trigger a cascade of responses in related pathways that could include TMEM220's activation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
db-cAMP is a cell-permeable cAMP analog that activates PKA. Upon activation, PKA may target TMEM220 if it is among its substrates, altering its function. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, elevating intracellular calcium levels. This can activate calcium-dependent kinases which then might phosphorylate TMEM220, assuming it interacts with these kinases. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates PKC, which is involved in various signaling pathways. PKC can phosphorylate numerous proteins, and if TMEM220 is a PKC substrate, its activation state can be modified. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, but by inhibiting PI3K, it can cause compensatory activation in related pathways that may converge on TMEM220, leading to its activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which may lead to adjustments in related signaling networks that could converge on and activate TMEM220. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, triggering a cascade of responses in mTOR-related pathways, which may include the activation of TMEM220 if it is influenced by these pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits ROCK, affecting cytoskeletal dynamics and possibly leading to the activation of TMEM220 if it is associated with pathways influenced by ROCK. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, altering the p38 MAPK signaling pathway, which can lead to the activation of TMEM220 if it is a part of or regulated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2 and can modify the MAPK/ERK pathway, potentially leading to the activation of TMEM220 if it is regulated by this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which can influence the JNK signaling pathway and may lead to the activation of TMEM220 if it is involved in JNK pathway signaling. | ||||||